Earnings Summary

Arcus Biosciences Inc’s revenue jumped 8.37% since last year same period to $29Mn in the Q2 2023. On a quarterly growth basis, Arcus Biosciences Inc has generated 16% jump in its revenue since last 3-months.

Arcus Biosciences Inc’s net profit fell -12.56% since last year same period to $-75Mn in the Q2 2023. On a quarterly growth basis, Arcus Biosciences Inc has generated 6.25% jump in its net profits since last 3-months.

Arcus Biosciences Inc’s net profit margin fell -3.86% since last year same period to -258.62% in the Q2 2023. On a quarterly growth basis, Arcus Biosciences Inc has generated 19.18% jump in its net profit margins since last 3-months.

Arcus Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -1.06 - a -1.92% fall from last quarter’s estimates.

Arcus Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -1.06.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Arcus Biosciences Inc’s return on assets (ROA) stands at -0.15.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Arcus Biosciences Inc’s return on equity (ROE) stands at -0.44.